Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05992077
NA

Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia

Sponsor: ANRS, Emerging Infectious Diseases

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the effectiveness of sofosbuvir/daclatasvir combination for children aged ≥ 6 years old and adolescents with active HCV infection in Cambodia

Official title: Pilot Therapeutic Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia

Key Details

Gender

All

Age Range

6 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

21000

Start Date

2023-08-07

Completion Date

2026-01-31

Last Updated

2025-12-04

Healthy Volunteers

No

Conditions

Interventions

DRUG

Sofosbuvir/Daclatasvir

Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.

Locations (4)

Battambang Provincial Hospital

Battambang, Cambodia

Kantha Bopha Hospital

Phnom Penh, Cambodia

National Pediatric Hospital

Phnom Penh, Cambodia

Jayavarman VII Hospital

Siem Reap, Cambodia